Last updated on March 2020

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors


Brief description of study

This is an open-label, First-in-Human, dose escalation and dose expansion study of THOR-707 (Monotherapy and Combination Therapy) in adult subjects with advanced or metastatic solid tumors.

Detailed Study Description

This is a First-in-Human, open-label, multiple ascending dose escalation and dose expansion study of THOR-707 in adult subjects with advanced or metastatic solid tumors. The objectives of the dose escalation phase are to identify the recommended phase 2 dose (RP2D) of THOR-707 as a monotherapy (Part 1) and in combination with a checkpoint inhibitor (Part 2); to evaluate safety/tolerability of THOR-707; to evaluate anti-tumor activity of THOR-707; to evaluate pharmacokinetics of THOR-707; and to evaluate various immunological biomarkers preand post-treatment with THOR-707. The objectives of the dose expansion phase (Part 3) are to further evaluate safety and anti-tumor activity of THOR-707 (administered at the RP2D) as a monotherapy and in combination with a checkpoint inhibitor in select populations of patients with advanced or metastatic solid tumors.

Clinical Study Identifier: NCT04009681

Find a site near you

Start Over

Synthorx Investigational Site

Melbourne, Australia
5.26miles
  Connect »